More scrutiny of physician-industry ties
This article was originally published in The Gray Sheet
Executive Summary
Medtronic consultant, University of Minnesota professor and spine surgeon David Polly, Jr., M.D., is targeted in an ongoing investigation led by Sen. Chuck Grassley, R-Iowa, into financial ties between medical professionals and device firms. In 2006, Polly lobbied extensively for continued funding of Department of Defense research into combat-related injuries, ultimately receiving DOD funds to head an animal study involving Medtronic's Infuse bone growth morphogenic protein. But in Senate testimony on behalf of the DOD funding, Polly did not disclose his consulting relationship with Medtronic, Grassley charges in a July 24 1letter to Polly's institution. The doctor billed Medtronic more than $50,000 for months of grant lobbying, according to the senator, and received upwards of $1.2 million in consulting fees and expenses from the firm between 2003 and 2007. Grassley sent a separate letter to the National Naval Medical Center on July 29 asking about its policies on physician financial disclosure reporting and conflicts of interest. Grassley sought responses to both letters by Aug. 7
You may also be interested in...
Surgeon-consultant resigns from orthopedic society
University of Minnesota surgeon David Polly, Jr., M.D., resigns his position on the board of the American Academy of Orthopaedic Surgeons in an Aug. 19 letter. Polly, who had undisclosed consulting ties to Medtronic, is the target of an ongoing investigation by Sen. Chuck Grassley, R-Iowa, into financial ties between medical professionals and device firms (1"The Gray Sheet" Aug. 10, 2009). Polly became an AAOS board member and secretary of AAOS' board of specialty societies in February
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.